by Targeting the Extracellular Matrix
Symic Bio has developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. These therapeutics are inspired by naturally occurring macromolecules of the extracellular matrix called proteoglycans. Symic Bio focuses on the extracellular matrix to enable new pathways to achieving therapeutic objectives.
Symic Bio is currently developing two clinical candidates, one for the treatment of critical limb ischemia (SB-030) and one designed for disease modification in the treatment of osteoarthritis (SB-061). In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.
Typically, therapeutic approaches are designed to address disease processes from outside the cell (e.g., intracellular targets or cell surface receptors). The library of compounds designed by Symic Bio target extracellular matrix components which are found outside the cell (e.g., collagen, hyaluronic acid).
“In the future, agents and compounds targeting directly the extracellular matrix will significantly advance the treatment of various human diseases, even those for which efficient therapies are not yet available.” – Järveläinen et al., 2009